Shanghai YaKe

Shanghai Yake Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies and solid tumors. Founded in 2015 and headquartered in Shanghai, the company has established a robust pipeline targeting antigens such as CD19, CD22, CD20, and BCMA. Yake Biotech is particularly recognized for its clinical research in multi-target CAR-T therapies, such as dual CD19/CD22 constructs, which aim to overcome antigen escape and reduce relapse rates in leukemia and lymphoma patients. The company operates its own R&D and GMP-compliant manufacturing facilities to support its clinical trials and future commercialization. With a focus on precision medicine, Yake Biotech continues to advance its cell therapy candidates through various stages of clinical development in China.